Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination

Cancer Epidemiology

Volumn 36, Issue 6, 2012, Pages 519-524

  Mollers, M ^a,b   Scherpenisse, M ^a,b   van der Klis, F R M ^a   King, A J ^a   van Rossum, T G J ^c   van Logchem, E M ^a   Feltkamp, M C ^a,d   Meijer, C J L M ^b   Snijders, P J F ^b   Boot, H J ^a   de Melker, H E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibodies; Human papillomavirus (HPV); Monitoring; Prevalence; Serology; The Netherlands; Vaccination

Indexed keywords

HUMAN PAPILLOMAVIRUS DNA; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ARTICLE; FEMALE; GENITAL TRACT INFECTION; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 6; HYBRIDIZATION; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEXUAL BEHAVIOR; VAGINA SMEAR; VIRUS LIKE AGENT; WART VIRUS;

ADOLESCENT; ANTIBODIES, VIRAL; COHORT STUDIES; DNA, VIRAL; FEMALE; HUMANS; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; SEXUAL BEHAVIOR; UTERINE CERVICAL DISEASES;

EID: 84868303156     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.07.006     Document Type: Article

References (20)

1. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
2. de Sanjose S., Diaz M., Castellsague X., et al. Worldwide prevalence and genotype distribution of invasive cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7:453-459.
3. Kjaer S.K., Sigurdsson K., Iversen O.E., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2:868-878.
4. Munoz N., Kjaer S.K., Sigurdsson K. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010, 102:325-339.
5. Romanowski B., de Borba P.C., Naud P.S., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.
6. De Carvalho N., Teixeira J., Roteli-Martins C.M., et al. Sustained efficacy and immunogenicity of the HPV-16/18 ASO4-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28:6247-6255.
7. Dalstein V., Riethmuller D., Prétet J.L., et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003, 106:396-403.
8. Dillner J., Arbyn M., Dillner L. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin Exp Immunol 2007, 148:199-207.
9. Carter J.J., et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996, 174(5):927-936.
10. Ho G.Y.F., et al. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prevent 2004, 13(1):110-116.
11. Kleter B., van Doorn L.J., Schrauwen L., et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999, 37:2508-2517.
12. Kleter B., van Doorn L.J., Ter Schegget J., et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998, 153:1731-1739.
13. Opalka D., Lachman C.E., MacMullen S.A., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003, 10(1):108-115.
14. Opalka D., Matys K., Bojczuk P., et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 2010, 17(5):818-827.
15. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297:813-819.
16. Roteli-Martins C.M., de Carvalho N.S., Naud P.S., et al. Prevalence of human papillomavirus infection and associated risk factors in young women in Brazil, Canada, and the United States: a multicenter cross-sectional study. Int J Gynecol Pathol 2011, 30(2):173-184.
17. Burchell A.N., Winer R.L., de Sanjose S., Franco E.L. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006, 24(S3):52-61.
18. Doerfler D., Berhaus A., Kottmel A., Sam C., Koelle D., Joura E.A. Human papilloma virus infection prior to coitarche. Am J Obstet Gynecol 2009, 200:487.
19. Anonymous. Statline Statistics Netherlands. [accessed November 2010]. http://statline.cbs.nl/.
20. Bakker F., de Graaf H., de Haas S., et al. Seksuele gezondheid in Nederland 2009 2009, Rutgers Nisso Groep, Utrecht, p. 5-90.